Clinical Trial Update: Clinical Study of the Therapeutic Effectiveness of In-silico-Designed, Machine Learning Inspired, and Quantum-molecularly Coupled Personalized Neoantigenic Vaccines Microlyvaq™ in Patients With Advanced Non-small Cell Lung Cancer [EARLY_Phase 1]

View source ↗

Summary

Early Phase 1 update on Microlyvaq™, a personalized neoantigenic vaccine designed with in-silico, machine-learning, and quantum-molecular coupling, for advanced…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer
• Squamous Cell Carcinoma of the Lung

Drugs mentioned

• Microlyvaq™

Snippet

Sponsor: Biogenea Pharmaceuticals Ltd. | Conditions: NSCLC (Non-small Cell Lung Cancer), Squamous Lung Cancer With FGFR1 Amplification | EARLY_Phase 1 | Status: ENROLLING_BY_INVITATION